[{"id":"a3114f80-afef-47f7-b876-49741eb531d9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05417321","created_at":"2022-06-14T22:56:23.088Z","updated_at":"2024-07-02T16:35:48.536Z","phase":"Phase 1/2","brief_title":"A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05417321","lead_sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","biomarkers":" ALK","pipe":" | ","alterations":" ALK mutation","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HB0036"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/25/2022","start_date":" 08/25/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2023-05-09"}]